Semaglutide
→Safety

2

1

7

↑2

↓1

—7

Evidence suggests Semaglutide haslittle to no effecton Safety.

12 studies (10 claims)

Moderate consensus

Study Claims

9 of 12

Intervention	Direction	Endpoint	Type	Population	Dosage	Title
semaglutide 2.4 mg	Increases - were generally associated with increased risk of	safety issues	Human	adults with body mass index ≥ 25 (or ≥ 23 for Asian populations)	—	The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.
once-weekly semaglutide 1.0 mg s.c.	No effect - had comparable safety profiles	safety profiles	Human	subjects with type 2 diabetes	—	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
semaglutide	Decreases - seem reasonable options	CV safety	Human	patients with CV disease	—	Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
semaglutide	No effect - reviewed	efficacy, safety profile, impact on different comorbidities	Human	patients with obesity in Brazil	—	Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
semaglutide (SEM)	Increases - had	Individual Case Safety Reports (ICSRs) reported in EudraVigilance	Human	—	—	An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.
semaglutide	No effect - there were no unexpected safety issues	safety	Human	participants with normal hepatic function or mild, moderate or severe hepatic impairment	—	Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
semaglutide	No effect - maintaining a well-tolerated	safety profile	Human	patients with NAFLD	Not specified	Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.cited 20×
semaglutide	No effect - similar	safety profile	Human	Japanese and Caucasian subjects	—	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.
semaglutide	No effect - No substantially increased risk was observed	select safety end points	Human	patients with cardiometabolic HFpEF	—	Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.